<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003075</url>
  </required_header>
  <id_info>
    <org_study_id>ID92-027</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-ID-92027</secondary_id>
    <secondary_id>NCI-P97-0092</secondary_id>
    <secondary_id>CDR0000065761</secondary_id>
    <nct_id>NCT00003075</nct_id>
  </id_info>
  <brief_title>Fenretinide in Treating Patients With Cervical Neoplasia</brief_title>
  <official_title>A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide
      may be effective in treating cervical neoplasia and preventing cervical cancer.

      PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of
      fenretinide to placebo in treating patients with cervical neoplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of fenretinide (N-(4-hydroxyphenyl) retinamide; 4-HPR)
      at regressing cervical intraepithelial neoplasia (CIN). II. Document the qualitative and
      quantitative toxicity of 4-HPR in women with CIN.

      OUTLINE: This is a double blinded study. Patients are randomized to receive either
      fenretinide or placebo. Patients are administered fenretinide or a placebo by mouth (PO)
      daily for 6 months with 3 days of rest every month. Patients undergo colposcopy,
      colpophotography, and Pap smears at 3, 6, 9, and 12 months. Patients undergo cervical biopsy
      at 6 and 12 months to assess changes.

      PROJECTED ACCRUAL: 84-100 patients will be accrued.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1992</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Fenretinide at Regressing CIN</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Fenretinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenretinide</intervention_name>
    <description>Oral Fenretinide daily for 6 months with 3 days of rest every month.</description>
    <arm_group_label>Fenretinide</arm_group_label>
    <other_name>4-HPR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo daily for 6 months with 3 days of rest every month.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically diagnosed new or recurrent cervical intraepithelial
        neoplasia grade 2-3 lesion involving at least one quadrant of the transformation zone of
        the cervix

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:
        At least 12 months Hematopoietic: Absolute granulocyte count greater than 1500/mm3 Platelet
        count greater than 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal:
        Creatinine no greater than 1.5 mg/dL Other: Fertile patients must use effective
        contraception Fasting triglyceride less than 2 times normal No prior malignancy Must
        consent to colposcopy and cervical biopsy

        PRIOR CONCURRENT THERAPY: Not specified
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Follen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>cervical intraepithelial neoplasia grade 2</keyword>
  <keyword>cervical intraepithelial neoplasia grade 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

